We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
-6.18%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$20.6B
AUM Growth
-$2.22B
Cap. Flow
+$62.6M
Cap. Flow %
0.3%
Top 10 Hldgs %
83.49%
Holding
126
New
5
Increased
17
Reduced
8
Closed
5

Top Buys

Rank Stock Value
1
TRDA icon
Entrada Therapeutics
TRDA
+$114M
2
INCY icon
Incyte
INCY
+$108M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$46.7M
4
TSVT
2seventy bio
TSVT
+$26M
5
TVTX icon
Travere Therapeutics
TVTX
+$17.7M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$66.1M
2
FLGT icon
Fulgent Genetics
FLGT
+$17.5M
3
BLUE
bluebird bio
BLUE
+$16M
4
MIRM icon
Mirum Pharmaceuticals
MIRM
+$12.9M
5
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$11.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.22%
2 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XENE icon
51
Xenon Pharmaceuticals
XENE
$5.88B
$23.5M 0.11%
751,639
– –
DBVT
52
DBV Technologies
DBVT
$914M
$23.4M 0.11%
1,461,426
– –
AXSM icon
53
Axsome Therapeutics
AXSM
$10.9B
$23.1M 0.11%
610,970
+71,913
+13% +$2.65M
JBIO
54
Jade Biosciences
JBIO
$1.36B
$21.6M 0.11%
52,337
+5,132
+11% +$2.6M
TSVT
55
DELISTED
2seventy bio
TSVT
$21.4M 0.1%
+833,236
New +$26M
FLGT icon
56
Fulgent Genetics
FLGT
$548M
$20.3M 0.1%
201,444
-199,572
-50% -$17.5M
NGNE icon
57
Neurogene
NGNE
$773M
$18.4M 0.09%
191,087
– –
OTIC
58
DELISTED
Otonomy, Inc.
OTIC
$16.3M 0.08%
7,844,692
+150,654
+2% +$310K
SYRE icon
59
Spyre Therapeutics
SYRE
$9.39B
$16.2M 0.08%
136,404
– –
BCAB icon
60
BioAtla
BCAB
$5.3M
$16.2M 0.08%
16,500
– –
SRZN icon
61
Surrozen
SRZN
$282M
$16.1M 0.08%
166,667
– –
REPL icon
62
Replimune Group
REPL
$1.39B
$16.1M 0.08%
593,395
+439,883
+287% +$13.2M
DICE
63
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$14.9M 0.07%
588,235
– –
ANAB icon
64
AnaptysBio
ANAB
$1.71B
$14.8M 0.07%
427,179
– –
AFMD
65
DELISTED
Affimed
AFMD
$14.6M 0.07%
265,317
+248,856
+1,512% +$15.4M
ACHL
66
DELISTED
Achilles Therapeutics
ACHL
$13M 0.06%
2,591,366
– –
CNTA
67
DELISTED
Centessa Pharmaceuticals
CNTA
$12.7M 0.06%
1,127,273
– –
TCDA
68
DELISTED
Tricida, Inc. Common Stock
TCDA
$12.3M 0.06%
1,285,014
+247,582
+24% +$1.6M
RLMD icon
69
Relmada Therapeutics
RLMD
$494M
$11.2M 0.05%
495,113
+294,117
+146% +$6.54M
SRPT icon
70
Sarepta Therapeutics
SRPT
$1.98B
$11.1M 0.05%
+123,456
New +$10.6M
BCEL
71
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$10.7M 0.05%
3,532,760
– –
LONA
72
LeonaBio Inc
LONA
$72.4M
$10.5M 0.05%
80,637
– –
ALT icon
73
Altimmune
ALT
$605M
$9.82M 0.05%
1,072,038
– –
CYT
74
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
$9.24M 0.05%
812,640
– –
KRTX
75
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$9.17M 0.04%
69,966
– –
1 2
3
4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q4 2021 Portfolio in Review

As of Q4 2021, Julian Baker held 126 positions worth $20.6B, down 9.7% from $22.8B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Julian Baker's Q4 2021 filing shows 5 new, 17 increased, 8 reduced and 5 closed positions. Its largest new stake was Entrada Therapeutics: 4,704,419 shares worth $80.5M. The largest sale was Seagen Inc. Common Stock, an estimated $66.1M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.

  • Julian Baker's largest Q4 2021 buy was Entrada Therapeutics: 4,704,419 shares worth $80.5M.
  • Julian Baker added most to Incyte in Q4 2021, an estimated $108M increase.
  • Julian Baker's biggest Q4 2021 reduction was Seagen Inc. Common Stock, cutting an estimated $66.1M.
  • Julian Baker fully exited Mirum Pharmaceuticals in Q4 2021, selling an estimated $12.9M.
  • Julian Baker's ten largest holdings make up 83% of its $20.6B portfolio in Q4 2021.
  • Julian Baker opened 5 new positions and closed 5 in Q4 2021.
  • Julian Baker's portfolio value fell 9.7% quarter-over-quarter to $20.6B.

Based on Baker Bros. Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.